Abstract
Objectives
We aimed to produce clinical recommendations for colonoscopic surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel diseases.
Materials and methods
The Danish Society for Gastroenterology and Hepatology convened a committee to assess the literature on colorectal cancer in inflammatory bowel diseases and the effectiveness of colonoscopy surveillance, according to the Oxford Centre for Evidence Based Medicine levels of evidence.
Results
Clinical recommendations for the colonoscopic surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel diseases were produced. These guidelines cover the risk stratification, entry, and follow-up of patients in the colonoscopy programme, the choice of image-enhanced colonoscopy modality, the investigation and treatment of lesions, and the management of special patient populations in the colonoscopy programme.
Conclusions
Colonoscopic surveillance of inflammatory bowel disease is thought to be associated with a decreased risk of colorectal cancer and colorectal cancer-related mortality. Further evidence regarding the effectiveness of colonoscopic surveillance will contribute to understanding its role in the management of inflammatory bowel diseases. The Danish Society for Gastroenterology and Hepatology clinical guideline will aid gastroenterologists in the risk stratification of patients with inflammatory bowel disease, and the management of colorectal lesions. Gastroenterologists must inform and support patients with inflammatory bowel disease to decide whether to participate in the colonoscopic surveillance programme.
Correction Statement
This article has been corrected with minor changes. These changes do not impact the academic content of the article.
Author contributions
CLAA is the guarantor of the article. DW, AN, JWH, LBR, ANT, AT, TJ, CLAA study concept design, data extraction, analysis and interpretation of data, drafting of the manuscript.
All authors approved the final version of the article, including the authorship list.
Disclosure statement
DW declares no conflicts of interest.
AN declares no conflicts of interest.
JWH declares no conflicts of interest.
LBR declares no conflicts of interest.
ANT declares no conflicts of interest.
TJ declares no conflicts of interest.
CLAA Advisory Boards: Ferring, Tillotts, Takeda, and Janssen